bluebird bio (NASDAQ:BLUE) Upgraded at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of bluebird bio (NASDAQ:BLUE) from an underweight rating to a neutral rating in a report issued on Monday morning, MarketBeat Ratings reports.

Other equities analysts have also issued research reports about the stock. Royal Bank of Canada restated a “sector perform” rating and issued a $80.00 target price on shares of bluebird bio in a report on Friday, November 15th. Barclays boosted their price objective on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st. StockNews.com started coverage on bluebird bio in a research note on Friday, December 20th. They set a “sell” rating for the company. Finally, Bank of America lowered bluebird bio from a “buy” rating to a “neutral” rating and dropped their price target for the company from $60.00 to $10.00 in a research note on Friday, November 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, bluebird bio currently has a consensus rating of “Hold” and a consensus price target of $44.14.

bluebird bio Stock Performance

Shares of BLUE stock opened at $3.86 on Monday. The stock has a market capitalization of $37.53 million, a PE ratio of -0.10 and a beta of 0.68. The business’s 50 day simple moving average is $7.63 and its 200 day simple moving average is $9.25. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. bluebird bio has a one year low of $3.56 and a one year high of $38.40.

Institutional Investors Weigh In On bluebird bio

Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC grew its position in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 74,185 shares during the period. FMR LLC grew its holdings in shares of bluebird bio by 8.1% during the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock valued at $1,289,000 after buying an additional 186,903 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of bluebird bio by 2,270.2% during the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 355,562 shares in the last quarter. Captrust Financial Advisors raised its holdings in shares of bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 77,293 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in bluebird bio in the 3rd quarter valued at about $42,000. Institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.